Cetuximab Does Not Improve Outcomes for Esophageal Cancer Chemoradiation
Cetuximab does not improve overall survival or clinical complete response rates for esophageal cancer chemoradiation.
Gastrointestinal (GI) Cancers Symposium
Risk Factors Should Prompt Endoscopic Screening for High-risk Gastric Cancer
Early detection of high-risk, presymptomatic gastric cancer with endoscopic screening is associated with improved survival.
Everolimus Failed to Improve Survival in Advanced HCC
Data indicate that everolimus did not improve overall survival in patients with advanced HCC following sorafenib failure.
Second-Line Trastuzumab Active in HER2-positive Advanced/Recurrent Gastric Cancer
Second-line treatment with paclitaxel/trastuzumab showed promising activity in trastuzumab-naïve patients with HER2-positive gastric cancer.
Poorer Survival Observed with MET-positive Stage IV Gastric Tumors
Patients with stage IV gastric tumors positive for MET protein expression have poorer survival than those without MET expression.
KRAS/NRAS Mutations Predict Panitumumab Nonresponsiveness in Metastatic CRC
Panitumumab plus second-line FOLFIRI chemotherapy is unlikely to improve outcomes in mCRC tumors harboring RAS mutations.
Neoadjuvant Capecitabine Equivalent to 5-FU for Rectal Cancer
Oral capecitabine plus neoadjuvant radiation offers equivalent outcomes and toxicity profiles compared to 5-fluorouracil (5-FU) plus radiation.
CAPTEM Offers Long-lasting Neuroendocrine Tumor Control
Combination capecitabine and temozolomide offer long-lasting neuroendocrine tumor control for patients whose tumors haven’t responded to standard therapy.
Second-Line Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer
Compared with paclitaxel alone, combining ramucirumab with paclitaxel increased survival in metastatic gastric cancer.
Vaccine Combination Improves Survival in Metastatic Pancreatic Cancer
The combination of two anticancer vaccines, as compared with one vaccine, doubled overall survival in metastatic pancreatic cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in GI Cancers Symposium 2014
Loading... 
Loading...